Daré Bioscience, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge Massachusetts United States (2005)

Organization Overview

First Clinical Trial
2020
NCT04370548
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Daré Bioscience, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

clindamycin (cleocin) (2 trials)

Drugs in Phase 2 Trials (2)

sildenafil (viagra) (2 trials)

tamoxifen (nolvadex) (1 trial)

Drugs in Phase 1 Trials (1)

diclofenac (voltaren) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Vaginal Diseases (Phase 3)

Vaginosis, Bacterial (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 4